Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to two new employees to purchase an aggregate of 65,000 shares, effective December 1, 2025. The awards were approved by the Compensation Committee under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $27.95 per share, equal to the last reported Nasdaq sale price on December 1, 2025. The grants are subject to the Inducement Plan terms.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, OLMA gained 0.37%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
OLMA was up 15.43% while key biotech peers ARVN, SAGE, BCAX, ORKA and VSTM showed declines between about -0.69% and -5.7%, indicating stock-specific strength rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Inducement option grants | Neutral | +0.4% | Reported 65,000-share employee stock option grants under 2022 Inducement Plan. |
| Nov 21 | Conference participation | Neutral | +8.1% | Planned fireside chat at Evercore Healthcare Conference with webcast access. |
| Nov 20 | Equity offering closed | Neutral | +13.3% | Closed $218.5M common stock offering including underwriters’ option exercise. |
| Nov 19 | Equity offering priced | Neutral | -3.5% | Priced 10,000,000-share public offering at $19.00 per share. |
| Nov 18 | Proposed offering | Neutral | +136.4% | Announced proposed common stock and pre-funded warrant offering from shelf. |
Over the last few months, Olema’s news flow has centered on capital markets activity, corporate events, and clinical progress. Multiple offerings in November 2025 raised significant equity financing, with price reactions ranging from -3.53% to +136.38%. Conference participation and routine items like inducement grants have also moved the stock, sometimes meaningfully. Earlier, a Phase 1b/2 update for palazestrant plus ribociclib and detailed quarterly filings outlined the company’s financial position and clinical strategy.
Market Pulse Summary
This announcement detailed inducement stock options for two new employees covering 65,000 shares at an exercise price of $27.95, vesting over 4 years under the 2022 Inducement Plan in line with Nasdaq Rule 5635(c)(4). It follows a series of recent equity offerings, clinical updates, and quarterly filings that outlined Olema’s funding and development plans. Investors may monitor future equity grants, clinical milestones, and additional capital markets activity as key markers.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
stock options financial
AI-generated analysis. Not financial advice.
SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 65,000 shares of the Company's common stock, effective as of December 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
What did Olema Oncology (OLMA) announce on December 2, 2025 about stock option grants?
What is the exercise price and term for the OLMA inducement options granted Dec 1, 2025?
How do the Olema (OLMA) inducement stock options vest?
Under what plan were the OLMA inducement awards granted and which Nasdaq rule applies?
Will the OLMA inducement grants immediately dilute existing shareholders?
Who approved the Olema inducement option grants for OLMA on Dec 1, 2025?
